Cargando…

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer

Castration-resistant prostate cancer (CRPC) with neuroendocrine differentiation (NED) is a lethal disease for which effective therapies are urgently needed. The mechanism underlying development of CRPC with NED, however, remains largely uncharacterized. In this study, we explored and characterized t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Shimiao, Tian, Hao, Niu, Xiaodan, Wang, Jiang, Li, Xing, Jiang, Ning, Wen, Simeng, Chen, Xuanrong, Ren, Shancheng, Xu, Chuanliang, Chang, Chawnshang, Flores-Morales, Amilcar, Shang, Zhiqun, Sun, Yinghao, Niu, Yuanjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756221/ https://www.ncbi.nlm.nih.gov/pubmed/30770901 http://dx.doi.org/10.1038/s41388-019-0750-5

Ejemplares similares

Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

AB007. Neurotensin derived from cancer stroma contributes to castration resistance via promoting neuroendocrine transdifferentiation
por: Zhu, Shimiao, et al.
Publicado: (2016)

LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex
por: Shang, Zhiqun, et al.
Publicado: (2019)

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

A switch from CD44(+) cell to EMT cell drives the metastasis of prostate cancer
por: Shang, Zhiqun, et al.
Publicado: (2014)

Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
por: Chen, Xuanrong, et al.
Publicado: (2020)

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients
por: Zhang, Zheng, et al.
Publicado: (2018)

YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
por: Jiang, Ning, et al.
Publicado: (2017)

Increased KIF4A expression is a potential prognostic factor in prostate cancer
por: Gao, Hongwei, et al.
Publicado: (2018)

YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
por: Shen, Tianyu, et al.
Publicado: (2020)

AB188. Vasohibin-1 and microvessel density predict prognosis in clear cell renal cell carcinoma
por: Tian, Hao, et al.
Publicado: (2016)

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts
por: WEN, SIMENG, et al.
Publicado: (2015)

Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer
por: Chen, Xuanrong, et al.
Publicado: (2021)

Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies
por: Zhu, Shimiao, et al.
Publicado: (2013)

Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression
por: Hu, Jieping, et al.
Publicado: (2018)

Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo
por: Iglesias-Gato, Diego, et al.
Publicado: (2015)

A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants
por: Jiang, Ning, et al.
Publicado: (2013)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

Correction: A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants
por: Jiang, Ning, et al.
Publicado: (2013)

Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
por: Li, Yang, et al.
Publicado: (2023)

HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2023)

Increased CK5/CK8-Positive Intermediate Cells with Stromal Smooth Muscle Cell Atrophy in the Mice Lacking Prostate Epithelial Androgen Receptor
por: Niu, Yuanjie, et al.
Publicado: (2011)

Imaging Neurotensin Receptor in Prostate Cancer With (64)Cu-Labeled Neurotensin Analogs
por: Deng, Huaifu, et al.
Publicado: (2017)

Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3
por: Chen, Xuanrong, et al.
Publicado: (2021)

Neutrophil–lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
por: Wang, Zhun, et al.
Publicado: (2018)

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
por: Merkens, Lina, et al.
Publicado: (2022)

Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival
por: Li, Gang, et al.
Publicado: (2017)

YAP is required for prostate development, regeneration, and prostate stem cell function
por: Xie, Hui, et al.
Publicado: (2023)

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer
por: Shang, Zhiqun, et al.
Publicado: (2016)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells
por: Pernicová, Zuzana, et al.
Publicado: (2014)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
por: Wen, Simeng, et al.
Publicado: (2020)

CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2021)

[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2023)

P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC
por: Zhang, Mingpeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5euvcg9eq6fi689ucst9tqk9nk